We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Aortech International Plc | AOR | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 126.50 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 126.50 |
| Top Posts |
|---|
Posted at 28/6/2020 12:18 by paleales #AOR #RUA Bill Brown, Chairman of RUA Life Sciences, takes us through a presentation on the new structure following the name change from AorTech International, and the acquisition of RUA Medical. |
Posted at 12/6/2020 09:32 by bones It is encouraging to see that Resonetics, the precision nitinol medical device parts makers are ploughing on with their expansion plans.In the last couple of years, Resonetics has taken a material stake in Medibrane, an Israeli based maker of polymer coverings for the same devices that Resonetics supplies the metal frames for, eg cardiovascular stents. There seems little doubt that the two companies are combining their respective skills to supply the major device makers of the globe. Hence why Aortech last year signed a major licensing deal with Medibrane, so that the latter company could start to design polymer covered products such as stents containing Elast-Eon, much the same way as RUA Medical Devices is doing with the products being developed by Aortech. Recalling the announcement last November (only just over 6 months ago); Elad Einav, CEO of Medibrane, said: ”We have already trialled the Elast-Eon(TM) material for some applications and found it to have a number of benefits over other polymers with regard to manufacturing process stability as well as cohesiveness. This coupled with the world class biocompatible and biostable properties of Elast-Eon(TM) should allow us to help grow the number of uses for Elast-Eon(TM) in medical devices.” Bill Brown, Chairman of AorTech, said: ”The AorTech team has been very impressed with Medibrane's technical capabilities and look forward to a long and successful partnership with them. We are delighted to be working with a commercially focused business such as Medibrane to help promote a greater number of Elast-Eon(TM) enabled medical devices.” This was hailed by Bill later in the Aortech half year report as ”....a very important licence agreement with Medibrane Limited, experts in encapsulation technology for medical devices but stents in particular....&rdquo It takes a long time for new products to be moved through the regulatory processes but I will be intrigued to know how this “very important” licence agreement is progressing. Perhaps we will get an update at the final results next month. The fact that Resonetics, a key partner of Medibrane, is expanding its operations must bode well. Knowing that Aortech have learned from the mistakes of the distant past, I am confident they will seek full value for their new licensing deals. The fruits of this deal will hopefully emerge in time as and when Elast-Eon enabled stents start to be approved. After all, stents represent a HUGE market! |
Posted at 09/6/2020 08:51 by bones I am grateful to no less than EIGHT of you that have so far requested a copy of my research PDF (laid out in post 3594). I am equally humbled by the kind responses! One respected, material shareholder of AOR even thought that it is the kind of material Shore Capital should be sending out to their clients! Very kind words.Judging by the replies, it is clear to me, by extrapolation, that there are many serious, long term shareholders of AOR lurking and observing from the shadows and it is encouraging that some have indicated that they will pass the document around their own circle of investor friends and associates. The more the general message can be circulated amongst serious players, the more that will take a look at the story unfolding here at Aortech/RUA. |
Posted at 04/6/2020 12:06 by ivor hunch CREO might not be a good direct comparison, but nevertheless the difference in figures is extraordinary. CREO revenue c£13,000 and pre-tax loss £18.6 million with marketcap £275 million: AOR revenue £470,000, loss just £0.6 million, marketcap £17.8 million. You really wonder how the market arrives at such very different valuations based on comparative figures. It's all to do with fashion, perception and presumably promotion by company brokers. |
Posted at 27/5/2020 08:26 by landy90 Comments from Shore Capital this morning:Trading Comments - AOR AORTECH INTERNATIONAL+ (AOR, House Stock, 105p) US patent granted/animal trials on grafts to begin AorTech has this morning announced that the United States Patent and Trademark Office has notified it that will issue a new patent in relation to its ElastEon technology. The invention relates to the process of manufacture of biomaterials for use in implantable medical devices including polymeric heart valves. We are encouraged by this development as AorTech looks to extend the life and range of its intellectual property protection. We also view positively the news that AorTech expects to commence animal testing on the ElastEon sealed graft in the coming weeks, which is at an earlier stage than we had anticipated at the time of the trading update on 12 May 2020. Our comment on the recent trading update flagged that we intend to publish a more detailed note on the likely implications of the RUA acquisition with updated forecasts at the time of the final results scheduled for July 2020. At that stage, we now also intend to set out a timeline of the potential significant milestones that will be achieved over the coming 12-18 months. HOUSE STOCK |
Posted at 19/5/2020 10:56 by langland There has been a number of informative posts on the thread in the last 12-18 months concerning the potential of a new polymer heart valve. In view of the recent HV developments I have revisited some of these posts and one which struck me is repeated below...landy90 - 19 Feb 2019 - 09:53:10 - 2390 of 3474 Aortech International – New Projects, New Partners, New Targets - AOR Below are the two major risks to the business of Edwards (mkt. cap. 44bn$), but it applies to all the major heart valve companies, especially those using animal tissue. A polymer valve is both a major threat and a solution to the top two risks. Polymer valves could be the next feeding frenzy. 1 Business and Operating Risks If we do not introduce new and differentiated products in a timely manner, our products may become more susceptible to competition or technologically obsolete and our operating results may suffer. The cardiovascular products industry is characterized by technological changes, frequent new product introductions, and evolving industry standards. Without the timely introduction of new and differentiated products, our products could become more susceptible to competition or technologically obsolete and our revenue and operating results would suffer 2 We may experience supply interruptions that could harm our ability to manufacture products. We use a broad range of raw and organic materials and other items from third party vendors in the design and manufacture of our products. Our Surgical Structural Heart, Transcatheter Aortic Valve Replacement, and Transcatheter Mitral and Tricuspid Therapies products are manufactured from treated natural animal tissue Some of our suppliers are located outside the United States. As a result, trade or regulatory embargoes imposed by foreign countries or the United States could result in delays or shortages that could harm our business. |
Posted at 10/5/2020 17:16 by langland While we wait for news of (hopefully) a resumption of RUA's core business, the R and D function has no doubt been working on the patches and grafts as well as the HV project. So, while I have till now taken as read that there is a market for these products I had not realised till recently quite how big the medtech world is. So here is a link to the top 40 global medtech companies.....It's quite a list. Presumably within this list are RUA/AOR's customers and potential customers and potential acquirers. RUA/AOR would be small change to one of these corporations. I am indirectly a shareholder in Fundamental Surgery (through my holding in TERN PLC) and it had occurred to me that its platform could be a vehicle for demonstrating RUA/AOR's products more readily. I am particularly mindful of the paragraph in the last RNS.....'Regulatory testing of the new graft is still anticipated in the second half of this year and the animal trials, in particular, are designed to demonstrate the grafts' performance targets of providing good surgical feel ......'FS's platform is the future for surgical training. Here is a link to its webinar series.. The really interesting part is from about 49 minutes in on the first webinar on the right. In particular this platform utilises haptic technology so this is what brought me back to 'good surgical feel' comment from the last RNS. |
Posted at 29/4/2020 09:39 by langland Decent reversal last 24 hours so one would like to think some canny buyers have shown up with anticipation that AOR/RUA will be the next 'big thing'. After all, if a dog like DEMG can double in the last week or so then why not AOR? But DEMG, which is also in the medtech sector, is strong because the market has just started waking up to the fact that it has valuable technology which would be attractive to the US market. How long before AOR/RUA follows suit? |
Posted at 15/3/2020 21:22 by bones I have been reviewing once more the recent research note by Equity Development (that attributed a valuation of 676p to AOR) and the recent RNS outlining the proposed acquisition of RUA Medical and subsequent reorganisation of the group into divisional subsidiaries (all very sensible in my book).It is always easy to read too much into things written but small paragraphs that jump out to me question their meanings or intentions to inform. In particular, in the ED research note, under the section on the Heart Valve division, there is this observation: ”We understand that AorTech has been in dialogue with potential licensors of its heart valve in order to use trial providers, designs and models that large medical device companies regard as validation for this type of product.” I note that this refers to using trial providers etc that have the blessing of the potential licensor majors which suggests some kind of licensing interaction before trials happen whereas I was thinking that majors would not be interested in any licensing before some kind of trial results had already been obtained. I dare say it is more subtle than this in reality but I go by what I read in the note. To enable such a thing to happen, it would be necessary to untangle all of the historic IP, patents and whatnot relating to the heart valve from everything else “Elast-EonR Then we have the new RUA proposals, amongst which is the intention to divisionalise all aspects of the previously tangled-up parts of Aortech, soon to be RUA Life Sciences plc. One part of the new structure will be the creation of “RUA Structural Heart”. An excerpt from The Chairman’s Letter dated 11th March 2020 says: ”Following Completion, AorTech Heart Valve Technologies Limited, a non-trading subsidiary of AorTech, will change its name to RUA Structural Heart and it is planned that it will hold the intellectual property relating to the Company’s synthetic heart valve.” This would ensure that the ducks are organised into the correct row in the event that the “understanding I guess we will see in time! |
Posted at 14/1/2020 14:41 by bones In the absence of any price action, it is worth (I find) keeping an eye on the general markets since, obviously, if we are entering a friendly market for smaller stocks, then we can expect individual shares to follow the general trend in the absence of specific drivers.I look at the FTSE AIM All-Share index from time to time since that is a solid indicator of sentiment in smaller AIM stocks. AOR has been volatile over the last two years but part of that action can be attributed to the sentiment governing the AIM All-Share. In Jan 2016, it bottomed at under 700, partly because it contains a good number of O&G and the oil price had cratered by that date. However, by summer 2018, the index had hit 1100 (up 65%) after a long bull market in overall shares. Yet, from the end of Sep 2018 to Dec 2018, the AIM All-Share crashed to 850 in the space of three months. Since then, it recovered mildly to 970 and fell back again to 850 but is now back to 965 on an upward trend. If it breaks through, chartists may argue that the 2018 peak of 1100 is its next stop. If you compare AOR’s movement since the fund raise in June 2018 to the AIM All-Share, you will get a better picture of why the stock has moved up and down so violently. The crucial thing for me is that AOR has now surpassed its 2018 highs whereas the AIM All-Share has 15% to go before catching its previous peak of 1100. The outperformance of AOR can be attributed to its improving work on the device developments but has it really received anything like the credit it should for what has been achieved since 2018? I personally think not! I hope the positive AIM All-Share trend will translate into a magnified out-performance by AOR as its success will hopefully be recognised while new investors looking to board the bull market may also pick up the shares. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
